Samples of body fluids such as blood, urine and plasma will be collected from the study subjects and will be analyzed for a novel biomarker using a biochemical and analytical assay from Medicortex. A special focus will be in catching the patients as soon as possible after the accident and time tracking of the biomarker levels following the injury.
In this clinical trial, Medicortex intends to collect body fluid samples of up to 160 patients who have sustained a head injury, and analyze for the existence of a brain injury biomarker between the patients and healthy control subjects. Based on our earlier laboratory animal tests and the phase one clinical test we can expect positive result from the study.
Dr. Marten Kvist, Medical Director of Medicortex: “We are excited to begin a second clinical study after the promising results of the first trial completed earlier this year. The study is to confirm the clinical relevance of this unique biomarker, and it will lead to development of a diagnostic aid for first responders and paramedics, it will help prioritize evacuation and reframe from administration of contraindicated medications.”
Medicortex is working towards the identification of a Traumatic Brain Injury (TBI) biomarker and incorporating it into a quick and reliable diagnostic kit that can be easily used by the first responders and healthcare professionals, and also by people with no medical profession.
Medicortex Finland Oy is a biotechnology company dedicated to developing diagnostics and treatments for brain injury and concussion. One of the company’s missions is to identify a new biomarker in order to reliably assess the severity and extent of brain injury. Medicortex was founded by Dr. Adrian Harel in Turku, Finland, in 2014 and it operates as a privately owned company. Dr. Harel is a neurobiologist and he has a track record in the business management and leadership of early-stage biotechnology companies.
This press release contains statements that are “forward-looking statements” that are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
Dr. Adrian Harel – CEO
Medicortex Finland Oy
Itäinen Pitkäkatu 4 B, FI-20520 Turku, Finland
Tel. +358 (0) 400 488 817
Fax. +358 (0) 2 251 0100
For the original news story, please visit https://pressreleasejet.com/news/a-new-clinical-trial-for-a-novel-brain-injury-biomarker.html.
Powered by WPeMatico
Latest posts by Brad Bennett (see all)
- Trimax Corporation Enters Cannabis Sector With the Acquisition of Omega Tech Inc. and Its Cutting Edge Ecommerce Business Recreational Dispensary - February 21, 2018
- Law Offices of Terry K. Davis Has a New Tustin Address - February 21, 2018
- Former XenoPort Chief Medical Officer, Richard Kim, MD, Joins NDA Partners as Expert Consultant - February 21, 2018